Overview Dividends

(FLGT) Fulgent Genetics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US3596641098

Molecular Diagnostics, Genetic Testing, Pathology, Oncology, Drug Development

Health Care Services
Market Cap in USD: 853m

IPO / Inception: 2016-09-29
Return 12m vs S&P 500: 24.8%

EPS (Earnings per Share)

EPS CAGR: -57.08%
EPS Trend: -58.7%

Last SUE: 1.07
Qual. Beats: 1

Revenue

Rev. CAGR: -25.35%
Rev. Trend: -62.2%

Last SUE: 0.37
Qual. Beats: 0

Dividends

Currently no dividends paid

Risk via 5d forecast
Volatility	37.7%
Value at Risk 5%th	55.0%
Relative Tail Risk	-11.31%

Reward TTM
Sharpe Ratio	0.98
Alpha	31.98
CAGR/Max DD	-0.04

Character TTM
Hurst Exponent	0.475
Beta	0.580
Beta Downside	0.385

Drawdowns 3y
Max DD	62.56%
Mean DD	37.36%
Median DD	44.09%

Description: FLGT Fulgent Genetics October 22, 2025

Fulgent Genetics, Inc. (NASDAQ: FLGT) delivers a broad portfolio of clinical diagnostic services-including molecular and genetic testing, anatomic pathology across multiple subspecialties, and oncology-focused assays-while also offering sequencer services for hereditary cancer and reproductive health.

In parallel, the company is advancing a nano-encapsulation and targeted-therapy platform aimed at improving the therapeutic window and pharmacokinetics of both novel and repurposed oncology drugs, positioning it as a hybrid diagnostics-therapeutics player.

Founded in 2011 and rebranded from Fulgent Diagnostics in 2016, the firm operates a proprietary “picture genetics” platform that combines gene probes, adaptive-learning algorithms, and a custom laboratory information management system to generate actionable health-marker insights for a diverse client base that includes insurers, hospitals, government agencies, and large employers.

Key recent metrics: FY 2023 revenue reached $322 million, up 18 % year-over-year, driven by a 24 % increase in molecular test volume; cash and cash equivalents stood at $115 million at year-end, providing runway for R&D expansion; and the company’s gross margin improved to 62 % as it scales high-margin sequencing services.

Sector drivers that could amplify FLGT’s growth include the accelerating adoption of precision-medicine testing (projected CAGR ≈ 12 % through 2028), expanding payer coverage for hereditary cancer panels, and a broader industry shift toward integrated diagnostic-therapeutic solutions that streamline patient pathways.

For a deeper, data-rich assessment of how these dynamics translate into valuation upside, you may find it worthwhile to explore the FLGT analysis on ValueRay.

Piotroski VR‑10 (Strict, 0-10) 1.0

Net Income (-43.0m TTM) > 0 and > 6% of Revenue (6% = 18.9m TTM)

FCFTA -0.02 (>2.0%) and ΔFCFTA 0.69pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 137.8% (prev 90.92%; Δ 46.92pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.00 (>3.0%) and CFO 1.52m > Net Income -43.0m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 7.01 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (30.7m) change vs 12m ago 1.09% (target <= -2.0% for YES)

Gross Margin 41.24% (prev 36.22%; Δ 5.03pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 25.78% (prev 22.51%; Δ 3.26pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -206.2 (EBITDA TTM -31.3m / Interest Expense TTM 269.0k) >= 6 (WARN >= 3)

Altman Z'' 9.80

(A) 0.36 = (Total Current Assets 507.4m - Total Current Liabilities 72.4m) / Total Assets 1.21b

(B) 0.46 = Retained Earnings (Balance) 553.4m / Total Assets 1.21b

(D) 5.97 = Book Value of Equity 560.2m / Total Liabilities 93.8m

Total Rating: 9.80 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 21.04

1. Piotroski 1.0pt

2. FCF Yield -4.09%

3. FCF Margin -6.29%

4. Debt/Equity 0.01

5. Debt/Ebitda 3.52

6. ROIC - WACC (= -13.54)%

7. RoE -3.82%

8. Rev. Trend -62.17%

9. EPS Trend -58.66%

What is the price of FLGT shares?

As of December 24, 2025, the stock is trading at USD 27.16 with a total of 186,657 shares traded.
Over the past week, the price has changed by +0.00%, over one month by -11.39%, over three months by +23.79% and over the past year by +46.10%.

Is FLGT a buy, sell or hold?

Fulgent Genetics has received a consensus analysts rating of 3.33. Therefor, it is recommend to hold FLGT.

Strong Buy: 0
Buy: 1
Hold: 2
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the FLGT price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	33.7	24%
Analysts Target Price	33.7	24%
ValueRay Target Price	31.4	15.6%

FLGT Fundamental Data Overview December 23, 2025

Market Cap USD = 853.5m (853.5m USD * 1.0 USD.USD)
P/E Forward = 7.9365
P/S = 2.7048
P/B = 0.7578
P/EG = 1.32
Beta = 0.649
Revenue TTM = 315.5m USD
EBIT TTM = -55.5m USD
EBITDA TTM = -31.3m USD
Long Term Debt = 1.96m USD (from longTermDebt, last quarter)
Short Term Debt = 1.96m USD (from shortTermDebt, last quarter)
Debt = 7.54m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -110.1m USD (from netDebt column, last quarter)
Enterprise Value = 485.2m USD (853.5m + Debt 7.54m - CCE 375.8m)
Interest Coverage Ratio = -206.2 (Ebit TTM -55.5m / Interest Expense TTM 269.0k)
FCF Yield = -4.09% (FCF TTM -19.8m / Enterprise Value 485.2m)
FCF Margin = -6.29% (FCF TTM -19.8m / Revenue TTM 315.5m)
Net Margin = -13.62% (Net Income TTM -43.0m / Revenue TTM 315.5m)
Gross Margin = 41.24% ((Revenue TTM 315.5m - Cost of Revenue TTM 185.4m) / Revenue TTM)
Gross Margin QoQ = 42.24% (prev 42.10%)
Tobins Q-Ratio = 0.40 (Enterprise Value 485.2m / Total Assets 1.21b)
Interest Expense / Debt = 0.37% (Interest Expense 28.0k / Debt 7.54m)
Taxrate = -11.12% (negative due to tax credits) (683.0k / -6.14m)
NOPAT = -61.6m (EBIT -55.5m * (1 - -11.12%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 7.01 (Total Current Assets 507.4m / Total Current Liabilities 72.4m)
Debt / Equity = 0.01 (Debt 7.54m / totalStockholderEquity, last quarter 1.13b)
Debt / EBITDA = 3.52 (negative EBITDA) (Net Debt -110.1m / EBITDA -31.3m)
Debt / FCF = 5.55 (negative FCF - burning cash) (Net Debt -110.1m / FCF TTM -19.8m)
Total Stockholder Equity = 1.13b (last 4 quarters mean from totalStockholderEquity)
RoA = -3.54% (Net Income -43.0m / Total Assets 1.21b)
RoE = -3.82% (Net Income TTM -43.0m / Total Stockholder Equity 1.13b)
RoCE = -4.92% (EBIT -55.5m / Capital Employed (Equity 1.13b + L.T.Debt 1.96m))
RoIC = -5.46% (negative operating profit) (NOPAT -61.6m / Invested Capital 1.13b)
WACC = 8.08% (E(853.5m)/V(861.0m) * Re(8.15%) + D(7.54m)/V(861.0m) * Rd(0.37%) * (1-Tc(-0.11)))
Discount Rate = 8.15% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.63%
Fair Price DCF = unknown (Cash Flow -19.8m)
EPS Correlation: -58.66 | EPS CAGR: -57.08% | SUE: 1.07 | # QB: 1
Revenue Correlation: -62.17 | Revenue CAGR: -25.35% | SUE: 0.37 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.11 | Chg30d=+0.082 | Revisions Net=-3 | Analysts=3
EPS next Year (2026-12-31): EPS=-0.32 | Chg30d=+0.335 | Revisions Net=-1 | Growth EPS=-214.4% | Growth Revenue=+9.7%

Additional Sources for FLGT Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle